5 products found

Elicio Therapeutics products

Angion - Inhibitor Program

Rho kinase (ROCK) signal transduction pathways are implicated in the development of fibrosis. Inhibition of the ROCK isoforms, ROCK1 and ROCK2, has shown promise in fibrosis; however, ROCK1 inhibition has been associated with inducing hypotension. Recent scientific work using specific genetic or pharmacological inhibition of ROCK2 indicates ROCK2 inhibition alone can result in anti-fibrotic activity without causing hypotension. These findings informed our strategy to develop ROCK2-specific inhibitors as a potential treatment of fibrosis. Dual ROCK1/2 inhibitors have been shown to have problematic side effects including hypotension and vascular permeability. However, in vivo studies involving compounds developed in our program may have stronger binding affinity for ROCK2 versus ROCK1. We believe high selectivity for ROCK2 could translate into a product candidate with enhanced tolerability that may support long-term systemic use.

Angion - Oral Small Molecule Tyrosine Kinase Receptor Inhibitor

ANG-3070 is a highly selective, oral small molecule tyrosine kinase receptor inhibitor developed internally as a potential treatment for chronic fibrotic diseases, particularly in the kidney and lung. In September of 2021, we held an R&D Day focused on the ANG-3070 program. You can view a recording of the event on our Events & Presentations page. ANG-3070 is an investigational product and is not approved by any regulatory authority.

Elicio - Multivalent Lymph Node–Targeted AMP Peptide Vaccine

ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.⁴ Mutations in the p53 protein lead to uncontrolled tumor progression and growth.⁴ Similar to Kristen rat sarcoma (KRAS), p53 mutations are present in a broad spectrum of cancer types, accounting for approximately 30% of solid tumors. We designed ELI-008 to target p53 hotspot mutations in solid tumor cancers, including melanoma, CRC, and non-small cell lung cancer (NSCLC).

Elicio - mKRAS Cancer Vaccine

Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ populations, that correlates with tumor biomarker responses, potentially leading to improved clinical outcomes.

Elicio - Multivalent Lymph Node–Targeted AMP Peptide Vaccine

ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.¹ BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of cancer, including 40% in melanoma, 9% in colorectal cancer (CRC), and 2% in lung cancer. High levels of BRAF protein expression in these tumors suggest susceptibility to T cells targeting the mutation.³ Previous research has shown a durable complete response through transfer of tumor-infiltrating lymphocytes recognizing mutated BRAF.³ By harnessing the ability to train T cells to target specific antigens, ELI-007 has the potential to generate tumor-specific immunity capable of eliminating BRAF-driven cancers.